Lexeo Therapeutics
LXEO | NASDAQ
$3.23
+$0.36 (+12.54%)
At close: Nov 16, 2026, 4:00 PM ET
$3.20
-$0.03 (-0.93%)
After-hours:
Nov 16, 2026, 7:59 PM ET
Lexeo Therapeutics Company Profile
Company profile explainedCompany Profile
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Key Executives
| Name | Position |
|---|---|
| R. Nolan Townsend | Chief Executive Officer & Director |
| Jose Manuel Otero | Chief Operating Officer |
| Louis Tamayo | Chief Financial Officer & Principal Accounting Officer |
| Ashley Kaplowitz | Head of Capital Markets |
| Keith Wonnacott | Senior Vice President of Regulatory Affairs |
| Narinder Bhalla FACC FSCAI | Chief Medical Officer |
| Ronald G. Crystal | Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board |
| Ryan McHenry | Vice President & Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | S-3 | Filing |
| Oct 13, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Sep 29, 2026 | 8-K | Current Report |
| Sep 28, 2026 | 4 | Filing |
| Sep 28, 2026 | 4 | Filing |
| Sep 28, 2026 | 4 | Filing |
| Sep 28, 2026 | 4 | Filing |
| Sep 22, 2026 | 8-K | Current Report |
| Aug 19, 2026 | 4 | Filing |
| Aug 19, 2026 | 4 | Filing |
Lexeo Therapeutics
| Country | United States |
| IPO Date | Nov 3, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 63 |
| CEO | R. Nolan Townsend |
Contact Details
345 Park Avenue South New York City,
New York 10010 United States
Stock Details
| Ticker Symbol | LXEO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001907108 |
| CUSIP Number | 52886X107 |
| ISIN Number | US52886X1072 |
| SIC Code | 2836 |
Add to Watchlist
Select watchlists to add or remove LXEO